Article
Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.
Blood advances - 8 Sept 2026
Short Nicholas J, Kantarjian Hagop, Daver Naval, Azevedo Roberta S, Karrar Omer, DiNardo Courtney D, Kadia Tapan, Yilmaz Musa, Maroun Manuel, Hachem Maria, Borthakur Gautam, Issa Ghayas C, Shpall Elizabeth J, Popat Uday, Huang Xuelin, Qiao Wei, Nasr Lewis, Macaron Walid, Abramova Regina, Garcia-Manero Guillermo, Konopleva Marina, Ravandi Farhad
Abstract excerpt
ABSTRACT: Among patients with FLT3-mutated acute myeloid leukemia (AML) who receive frontline azacitidine plus venetoclax, relapses are commonly driven by the expansion of the FLT3-mutated clone, supporting FLT3 inhibitor-based triplet lower-intensity regimens. We report long-term outcomes of a phase 2 study of azacitidine, venetoclax, and gilteritinib for adults with newly diagnosed FLT3-mutated AML who were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.